Pros and cons of treating murine myasthenia gravis with anti-C1q antibody

Erdem Tüzün, Jing Li, S. Shamsher Saini, Huan Yang, Premkumar Christadoss

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

To test the feasibility of classical complement pathway manipulation in experimental autoimmune myasthenia gravis (EAMG) treatment, C57BL/6 (B6) and RIIIS/J mice with EAMG were treated with 10 μg or 100 μg of anti-C1q Ab or isotype Ab. Treatment with 10 μg anti-C1q Ab significantly reduced the clinical severity, decreased lymph node cell IL-6 production and T cell populations. Conversely, administration of 100 μg anti-C1q Ab caused harmful side effects such as increased serum anti-acetylcholine receptor antibody, immune complex, C3 and lymph node B cell levels and kidney C3 and IgG deposits, which reduced the treatment efficacy.

Original languageEnglish (US)
Pages (from-to)167-176
Number of pages10
JournalJournal of Neuroimmunology
Volume182
Issue number1-2
DOIs
StatePublished - Jan 2007

Fingerprint

Autoimmune Experimental Myasthenia Gravis
Myasthenia Gravis
Anti-Idiotypic Antibodies
Lymph Nodes
Classical Complement Pathway
Cholinergic Receptors
Antigen-Antibody Complex
Interleukin-6
B-Lymphocytes
Immunoglobulin G
T-Lymphocytes
Kidney
Antibodies
Serum
Population

Keywords

  • Autoimmunity
  • C1q
  • Classical complement pathway
  • Myasthenia gravis

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

Pros and cons of treating murine myasthenia gravis with anti-C1q antibody. / Tüzün, Erdem; Li, Jing; Saini, S. Shamsher; Yang, Huan; Christadoss, Premkumar.

In: Journal of Neuroimmunology, Vol. 182, No. 1-2, 01.2007, p. 167-176.

Research output: Contribution to journalArticle

Tüzün, E, Li, J, Saini, SS, Yang, H & Christadoss, P 2007, 'Pros and cons of treating murine myasthenia gravis with anti-C1q antibody', Journal of Neuroimmunology, vol. 182, no. 1-2, pp. 167-176. https://doi.org/10.1016/j.jneuroim.2006.10.014
Tüzün, Erdem ; Li, Jing ; Saini, S. Shamsher ; Yang, Huan ; Christadoss, Premkumar. / Pros and cons of treating murine myasthenia gravis with anti-C1q antibody. In: Journal of Neuroimmunology. 2007 ; Vol. 182, No. 1-2. pp. 167-176.
@article{5383f48dbf1f481585af332de908fcbb,
title = "Pros and cons of treating murine myasthenia gravis with anti-C1q antibody",
abstract = "To test the feasibility of classical complement pathway manipulation in experimental autoimmune myasthenia gravis (EAMG) treatment, C57BL/6 (B6) and RIIIS/J mice with EAMG were treated with 10 μg or 100 μg of anti-C1q Ab or isotype Ab. Treatment with 10 μg anti-C1q Ab significantly reduced the clinical severity, decreased lymph node cell IL-6 production and T cell populations. Conversely, administration of 100 μg anti-C1q Ab caused harmful side effects such as increased serum anti-acetylcholine receptor antibody, immune complex, C3 and lymph node B cell levels and kidney C3 and IgG deposits, which reduced the treatment efficacy.",
keywords = "Autoimmunity, C1q, Classical complement pathway, Myasthenia gravis",
author = "Erdem T{\"u}z{\"u}n and Jing Li and Saini, {S. Shamsher} and Huan Yang and Premkumar Christadoss",
year = "2007",
month = "1",
doi = "10.1016/j.jneuroim.2006.10.014",
language = "English (US)",
volume = "182",
pages = "167--176",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Pros and cons of treating murine myasthenia gravis with anti-C1q antibody

AU - Tüzün, Erdem

AU - Li, Jing

AU - Saini, S. Shamsher

AU - Yang, Huan

AU - Christadoss, Premkumar

PY - 2007/1

Y1 - 2007/1

N2 - To test the feasibility of classical complement pathway manipulation in experimental autoimmune myasthenia gravis (EAMG) treatment, C57BL/6 (B6) and RIIIS/J mice with EAMG were treated with 10 μg or 100 μg of anti-C1q Ab or isotype Ab. Treatment with 10 μg anti-C1q Ab significantly reduced the clinical severity, decreased lymph node cell IL-6 production and T cell populations. Conversely, administration of 100 μg anti-C1q Ab caused harmful side effects such as increased serum anti-acetylcholine receptor antibody, immune complex, C3 and lymph node B cell levels and kidney C3 and IgG deposits, which reduced the treatment efficacy.

AB - To test the feasibility of classical complement pathway manipulation in experimental autoimmune myasthenia gravis (EAMG) treatment, C57BL/6 (B6) and RIIIS/J mice with EAMG were treated with 10 μg or 100 μg of anti-C1q Ab or isotype Ab. Treatment with 10 μg anti-C1q Ab significantly reduced the clinical severity, decreased lymph node cell IL-6 production and T cell populations. Conversely, administration of 100 μg anti-C1q Ab caused harmful side effects such as increased serum anti-acetylcholine receptor antibody, immune complex, C3 and lymph node B cell levels and kidney C3 and IgG deposits, which reduced the treatment efficacy.

KW - Autoimmunity

KW - C1q

KW - Classical complement pathway

KW - Myasthenia gravis

UR - http://www.scopus.com/inward/record.url?scp=33845884294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845884294&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2006.10.014

DO - 10.1016/j.jneuroim.2006.10.014

M3 - Article

VL - 182

SP - 167

EP - 176

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -